Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...161162163164165166167168169170171...10651066»
  • ||||||||||  methylprednisolone oral / Generic mfg., dexamethasone injection / Generic mfg.
    New P4 trial:  Methylprednisolone Taper, Lower Extremity (clinicaltrials.gov) -  May 15, 2023   
    P4,  N=200, Not yet recruiting, 
  • ||||||||||  avadomide (CC-122) / BMS
    Enrollment open:  A Rollover Study of CC-122 (clinicaltrials.gov) -  May 15, 2023   
    P1,  N=12, Recruiting, 
    Phase classification: P2 --> P=N/A Not yet recruiting --> Recruiting
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma, Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Journal:  COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies. (Pubmed Central) -  May 14, 2023   
    Finally, as CD19-targeted and B-cell maturation (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies become more heavily used for relapsed/refractory hematologic malignancies, viral infections including COVID-19 are increasingly recognized as common complications, but data on risk factors and prophylaxis in this patient population are scarce. We summarize the available evidence regarding viral infections after CAR T-cell therapy.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal, Surgery:  A comparison of prophylactic antiemetic therapy with palonosetron and dexamethasone as single-agents or in combination in adult patients undergoing laparoscopic surgery: A randomized trial. (Pubmed Central) -  May 14, 2023   
    Group P (n = 30) received palonosetron 0.075 mg intravenously (iv), Group D (n = 30) received dexamethasone 8 mg iv and Group P + D (n = 30) received palonosetron 0.075 mg and dexamethasone 8 mg iv...We found that the overall incidence of PONV was 46.7% in Group P, 50% in Group D, and 43.3% in Group P + D during the first 24 h. Rescue antiemetic was required in 27% of the patients in Group P and Group D compared to 23% of the patients in Group P + D and twice in 3% of the patients in Group P, 7% of the patients in Group D, and none in Group P + D which were not significant. The combination therapy of palonosetron plus dexamethasone did not significantly reduce the incidence of PONV when compared with either drug alone.
  • ||||||||||  dexamethasone / Generic mfg., ondansetron / Generic mfg.
    Retrospective data, Journal:  Antiemetic Administration and Its Association with Race: A Retrospective Cohort Study. (Pubmed Central) -  May 13, 2023   
    This evidence on drug effects may improve our understanding of pulmonary physiology and the pathophysiology of asthma. In a perioperative registry data set, Black versus White patient race was associated with less antiemetic administration, after controlling for all accepted postoperative nausea and vomiting risk factors.
  • ||||||||||  lenalidomide / Generic mfg.
    Journal:  Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy. (Pubmed Central) -  May 13, 2023   
    During lenalidomide-based treatment, the GR patients showed an increase in effector memory CD4+ and CD8+ T-cell subsets. These findings support distinct immune patterns in different clinical contexts, suggesting that deep immune profiling could be used for treatment guidance and warrants further exploration.
  • ||||||||||  dexamethasone / Generic mfg., captopril / Generic mfg.
    Review, Journal:  The role of confirmatory tests in the diagnosis of primary aldosteronism. (Pubmed Central) -  May 13, 2023   
    We recommend screening for ACS in patients with PA scheduled for AVS examinations as well as for adrenalectomy. We recommend the 1-mg overnight dexamethasone suppression test as screening method to detect ACS.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Successful subcutaneous desensitization to Dupilumab (Poster Zone A) -  May 13, 2023 - Abstract #EAACI2023EAACI_2259;    
    The symptoms responded well to Chlorphenamine maleate 10 mg and Methylprednisolone 40 mg intravenously...Desloratadine 5 mg was administered 30 minutes before the procedure...To our knowledge, this is the first reported case of desensitization to Dupilumab. Because no protocols existed, we established a new rapid subcutaneous desensitization protocol, which was well tolerated by the patient and allowed her to continue the administration wih the best treatment.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Successful treatment of hyper eosinophilic syndrome with dupilumab: A case report and review of the literature (Poster Zone A) -  May 13, 2023 - Abstract #EAACI2023EAACI_2225;    
    Case Report intoduction : Duplinumab is a human monoclonal antibody against interleukin (IL4 ) receptor that inhibit IL-4 receptor and IL 13 signaling It has demonstrated efficacy in treatment for many disease represent with the eosinophils infiltration to sites of inflammation, such as asthma, atopic dermatitis, chronic spontaneous urticaria, and eosinophilic esophagitis (1) case presentation :We report a middle age female , diagnosed with idiopathic hyper eosinophilic syndrome(HES ,presented with generalized lichenification and sever pruritus for 15 years , after failed treatment with steroid and benralizumab , the patient was treated with dupilumab resulting in significant improvement in pruritus discussion : Appropriate selection of therapy in HES required many considerations such as degree of eosinophilia or combined with end-organ failure , underlying pathophysiology of eosinophilia, and possible adverse effects of therapy. Several drug have been approved to treat HES including Steroid ,Cytotoxic agents , monoclonal anti
  • ||||||||||  dexamethasone injection / Generic mfg.
    Anaphylactic Reaction to Ciprofloxacin in a Hypertensive Patient (Poster Zone A) -  May 13, 2023 - Abstract #EAACI2023EAACI_2197;    
    It is essential to identify and report such reactions promptly to prevent future exposure and to avoid the use of other fluoroquinolones due to the risk of cross-reactivity. In addition, the case highlights the importance of obtaining a detailed medical history to identify potential risk factors for adverse drug reactions, such as hypertension and medication use.
  • ||||||||||  Rupex (rupatadine) / Incepta Pharma, Medexus
    Acquired angioedema with C1-inhibitor deficiency (AAE-C1-INH) (Poster Zone A) -  May 13, 2023 - Abstract #EAACI2023EAACI_1980;    
    Skin histopathological assessment revealed smooth epidermis, with segmental vacuole degeneration of the basal layer and basal hyperpigmentation. Moreover, presence of perivascular clusters of inflammatory cells, mainly granulocytes and lymphocytes with additional presence of dispersed neutrophils has been ascertained.
  • ||||||||||  dexamethasone / Generic mfg.
    Clinical, Journal:  Assessment of Corticosteroid Therapy and Death or Disability According to Pretreatment Risk of Death or Bronchopulmonary Dysplasia in Extremely Preterm Infants. (Pubmed Central) -  May 12, 2023   
    Most treated infants (363 [75.3%]) received dexamethasone...For death or cerebral palsy, the risk difference decreased by 3.6% (95% CI, 2.9%-4.4%) for each 10% increase in the risk of death or grade 2 or 3 BPD and transitioned from estimated net harm to benefit at a pretreatment risk of 40% (95% CI, 33%-46%). Results of this study suggested that corticosteroids were associated with a reduced risk of death or disability in infants at moderate to high pretreatment risk of death or grade 2 or 3 BPD but with possible harm in infants at lower risk.
  • ||||||||||  hydrocortisone / Generic mfg.
    Golden Hours and Secondary Prevention of PTSD (Place du Canada) -  May 12, 2023 - Abstract #CINP2023CINP_406;    
    Individuals who got those injections no later than 6 hours after exposure to the trauma ("The Golden Hours") were less likely to develop PTSD in 2 weeks, 1 month and 3 months as compared to the individuals who got placebo. The molecular mechanism of this finding and its relation to the prevention of consolidation of the traumatic memory will be presented.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Towards discovering a novel family of peptides targeting neuroinflammatory states of brain microglia and astrocytes. (Pubmed Central) -  May 12, 2023   
    Surveying glia were untreated, reactive were induced with a lipopolysaccharide (LPS) treatment, recovery was modelled with a potent anti-inflammatory treatment dexamethasone (Dex), and priming was determined by subsequently challenging the cells with interferon gamma (IFN?)...Fivety eight unique peptides were discovered, and their potential functions were assessed using a BLAST tool. Peptides potentially originated from proteins ranging in function from a variety of supportive glial roles, including synapse support and pruning, to inflammatory incitement including cytokine and interleukin activation, and potential regulation in neurodegenerative and neuropsychiatric disorders.
  • ||||||||||  Calquence (acalabrutinib) / AstraZeneca
    Trial completion date, Trial primary completion date:  Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma (clinicaltrials.gov) -  May 12, 2023   
    P2,  N=45, Recruiting, 
    Peptides potentially originated from proteins ranging in function from a variety of supportive glial roles, including synapse support and pruning, to inflammatory incitement including cytokine and interleukin activation, and potential regulation in neurodegenerative and neuropsychiatric disorders. Trial completion date: Aug 2028 --> Aug 2025 | Trial primary completion date: Aug 2023 --> Aug 2024
  • ||||||||||  ketorolac / Generic mfg.
    Enrollment open, Trial primary completion date, Head-to-Head:  Triamcinolone Ketorolac (TriKe) Knee Trial (clinicaltrials.gov) -  May 12, 2023   
    P4,  N=150, Enrolling by invitation, 
    N=14 --> 56 | Trial completion date: Aug 2026 --> Jul 2027 | Trial primary completion date: Nov 2024 --> Aug 2025 Not yet recruiting --> Enrolling by invitation | Trial primary completion date: May 2023 --> Sep 2023
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Enrollment open, Trial completion date, Trial primary completion date, MRI:  ETHA: Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma (clinicaltrials.gov) -  May 12, 2023   
    P3,  N=30, Recruiting, 
    Not yet recruiting --> Enrolling by invitation | Trial primary completion date: May 2023 --> Sep 2023 Not yet recruiting --> Recruiting | Trial completion date: Dec 2021 --> Dec 2024 | Trial primary completion date: Dec 2021 --> Dec 2024
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    ISA-KD IN NOT TRANSPLANT CANDIDATES RRMM. EXPERIENCE IN REAL LIFE. () -  May 12, 2023 - Abstract #EHA2023EHA_3166;    
    These data provide RWE to support Isa use in RRMM outside clinical trials and in wider populations. We reported fast response , and well tolerated regimen in elderly patients.
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK
    RELAPSING/REFRACTORY ABDOMINAL WALL EXTRA-MEDULLARY PLASMACYTOMAS DEMONSTRATING A RAPID COMPLETE RESPONSE TO BELANTAMAB MAFODOTIN () -  May 12, 2023 - Abstract #EHA2023EHA_3012;    
    He received standard RVD (Revlimid, Velcade and Dexamethasone) regimen for 7 cycles with very good partial response (VGPR)...He was switched to KRD (Carfilzomib, Revlimid and Dexamethasone) along with radiotherapy to the sternal lesions with very good response biochemically (SPEP, normal pattern) and radiologically (repeat CT PET scan showed no metabolically active disease with no residual mass)...The treatment was switched to DVD (Daratumumab, Velcade and Dexamethasone) with very good partial response... The extramedullary phase of Myeloma remains a major medical challenge and further studies are required to clarify the role of antibody-drug conjugates.